Streetbeat News

Products Services

ZVSA

ZyVersa Therapeutics published a paper in the Angiogenesis peer-review journal demonstrating that their Inflammasome ASC Inhibitor IC 100 restored retinal structure and function in an animal model of Retinopathy of Prematurity (ROP). The study showed that IC 100 suppressed retinal microglia activation, reduced retinal inflammation, and improved retinal function.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 3:20 pm

SLRX

Salarius Pharmaceuticals shares are trading lower after the company was notified by MD Anderson Cancer Center of a Grade 4 adverse event in the Seclidemstat clinical trial. The FDA has placed the trial on partial clinical hold, preventing new patient enrollment while allowing current patients to continue treatment.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 3:12 pm

GOOG

GOOGL

Google has announced the formation of the Coalition for Secure AI (CoSAI), aimed at ensuring the safe and secure development of artificial intelligence. Google is a founding member of this coalition.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 3:10 pm

LILM

Saudia Group has signed a global agreement to acquire 50 Lilium jets, with options to purchase 50 more. Financial terms of the deal were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 3:08 pm

NKGN

NKGen Biotech Inc (NASDAQ:NKGN) shares surged by 25% to $1.17 after announcing the presentation of new SNK01 biomarker data at the Alzheimer’s Association International Conference. The data shows SNK01’s potential in reducing α-synuclein, linked to cognitive decline in Alzheimer’s patients. The presentation will be held on July 30, 2024, with additional details available on NKGen’s website.

Portfolio Pulse from Henry Khederian

July 18, 2024 | 3:06 pm

ARTV

Artiva Biotherapeutics, Inc (NASDAQ:ARTV) is set to start trading on the NASDAQ exchange on July 19. The IPO price is expected to be between $14.00 and $16.00 per share, with an insider lock-up period of 180 days ending on January 15, 2025. Artiva is a clinical-stage biotechnology company focused on NK cell-based therapies for autoimmune diseases and cancers.

Portfolio Pulse from Benzinga Insights

July 18, 2024 | 3:00 pm

NVDA

The article discusses the recent pullback in Nvidia (NASDAQ: NVDA) shares and explores different narratives for the decline, including market rotation, potential tariffs, and concerns about the AI bubble. The author shares their strategy for trading Nvidia shares and options, emphasizing the use of price movement and technical indicators for entry and exit points. The author plans to buy Nvidia shares again if it appears in their top ten names and meets specific technical and valuation criteria.

Portfolio Pulse from David Pinsen

July 18, 2024 | 2:57 pm

CTAS

Cintas Corporation's executive has indicated that the company expects margin pressure on its fire protection business due to the implementation of SAP in fiscal year 2025.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 2:57 pm

SYTA

Siyata Mobile Inc (NASDAQ:SYTA) shares surged by 4.5% to $0.71 after announcing new orders for its SD7 handsets and related accessories worth over $4.5 million. CEO Marc Seelenfreund expects record sales in Q3 2024, driven by strong distribution channels and increasing adoption of the SD7 handset. Additionally, TJ Kennedy, former President of FirstNet, has joined Siyata's Advisory Board to enhance their public safety market presence.

Portfolio Pulse from Henry Khederian

July 18, 2024 | 2:56 pm

XOM

Exxon Mobil confirmed that its Joliet, Illinois refinery lost power during a tornado earlier this week.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 2:55 pm